Four months of Aimovig injections. No meaningful change. Or maybe Nurtec helped at first and then quietly stopped. Or you've been told you've exhausted the CGRP options and the neurologist isn't sure what to try next.
CGRP medications were supposed to be different. Not repurposed from epilepsy or blood pressure, but designed from scratch for migraine, targeting the molecule researchers identified as central to migraine pain. For roughly half of patients, they work well. For the other half, they don't.
That split isn't random. It reflects something real about migraine biology: CGRP is one pathway in a system with several, and for a large portion of people with migraine, it isn't the dominant one.
Why this matters
If CGRP medications haven't helped, that's not a dead end. It's a signal. It tells you CGRP isn't the main pressure point in your system, and that the investigation should shift toward the layers that CGRP blockade doesn't reach: hormones, histamine, vascular dynamics, and autonomic regulation.
Why standard answers miss the point
The standard next step after CGRP drugs fail is to try a different drug class or wait longer. That framing treats non-response as random variation.
The more precise explanation: CGRP drugs work when CGRP is the dominant driver. When they don't work, that's a mechanistic signal. It narrows the search considerably, pointing toward the layers (hormonal, histamine, vascular) that weren't being addressed. Cycling through more medications without this distinction leads most people in circles.
What CGRP Medications Actually Target
CGRP (calcitonin gene-related peptide) is a neuropeptide released by trigeminal nerve fibers during a migraine. It causes meningeal blood vessel dilation, promotes neurogenic inflammation, and sensitizes pain pathways. CGRP medications block this signaling in one of two ways:
Gepants (acute + preventive)
Nurtec (rimegepant), Ubrelvy (ubrogepant)
Small molecules that block the CGRP receptor. Work within hours. Some cross the blood-brain barrier. Can be taken acutely or every other day for prevention.
Monoclonal antibodies (preventive)
Aimovig, Ajovy, Emgality
Large proteins injected monthly (or quarterly). Provide sustained, 24/7 CGRP suppression for weeks. Work primarily in peripheral tissue; limited blood-brain barrier penetration.
Both approaches are highly targeted. That specificity is their strength, and the reason they fail when CGRP isn't the issue. Think of CGRP as one wire in a complex alarm system. Cutting that wire stops the alarm only if it was the wire running to the sensor that detected the problem. If the fire is in a room connected to a different sensor entirely, cutting the CGRP wire does nothing.
Why CGRP Blockade Misses the Other Layers
Standard migraine workups focus heavily on frequency and severity, then cycle through preventive options. CGRP drugs often come early in that sequence because they're targeted and well-tolerated. What they don't include is a structured investigation of which pathways are actually driving attacks.
The result is that many patients spend months on CGRP medications while the real drivers (hormonal swings, histamine load, blood pressure dynamics) continue unchecked.
Clinical clue
If your migraines follow a clear hormonal cycle, come with flushing or nasal congestion, worsen when you stand up or are dehydrated, or cluster around the same time each month, these patterns suggest specific non-CGRP layers worth raising with your clinician. Each has a distinct mechanistic explanation and is often investigable with standard workup.
The Four Layers CGRP Drugs Don't Reach
1. Hormonal layer: estrogen and progesterone fluctuations
Estrogen withdrawal (the drop that occurs before menstruation, around ovulation, or during the erratic swings of perimenopause) activates mast cells, lowers the migraine threshold, and triggers vasodilation through mechanisms that run parallel to CGRP, not through it. CGRP may be released downstream, but blocking it doesn't prevent the hormonal cascade that set it off.
This is why perimenstrual migraines and perimenopause migraines often don't respond to CGRP blockade alone. The trigger is the estrogen delta: the rate of drop, not the absolute level. That signal reaches the trigeminal system through pathways CGRP drugs don't intercept. Estrogen's dual role as both mast cell activator and vascular stabilizer makes this pattern particularly unpredictable.
Pattern clue: Migraines cluster in the 2-3 days before menstruation, at ovulation, or worsened significantly at perimenopause.
2. Inflammatory layer: histamine and mast cell activity
Histamine-driven migraines involve vasodilation and neuroinflammation mediated through H1, H2, and H4 receptors, not CGRP receptors. When histamine load crosses a threshold (accumulated from food, hormonal fluctuations, gut inflammation, or mast cell instability), the resulting vascular and neurological changes can trigger migraine through a pathway that CGRP blockade doesn't intercept.
The histamine-CGRP relationship is real: histamine can stimulate CGRP release, which means CGRP sometimes appears downstream of a histamine-driven attack. Blocking CGRP in that scenario is like treating the smoke; the histamine fire continues.
Pattern clue: Migraines come with flushing, nasal congestion, or skin reactions; food-related triggers are inconsistent (not every time, depends on what else is stacked that day).
3. Vascular layer: blood pressure and cerebral perfusion
In some migraine patterns, the trigger isn't excessive neuroinflammation but inadequate perfusion: the brain isn't getting enough blood flow. This mechanism operates through autonomic regulation, blood vessel tone, and intravascular volume, not through CGRP signaling. CGRP drugs don't improve cerebral blood flow or vascular tone in the direction these patterns require.
POTS-related migraines are the clearest example: when standing causes blood to pool in the legs and reduces brain perfusion, the brain compensates with vasodilation and neurogenic inflammation, a cascade that blocking CGRP doesn't prevent because the vascular underfill is still happening. The same logic applies to low blood pressure migraine patterns more broadly.
Pattern clue: Migraines worsen with dehydration, standing, heat, or skipped meals; better lying down; often come with low blood pressure readings.
4. Threshold accumulation: CGRP is one layer of many
Even in migraines where CGRP is genuinely involved, blocking it may not be enough if the total load is high. The threshold model treats migraine as the result of multiple stacking inputs: sleep disruption, stress, hormonal shifts, histamine accumulation, dehydration, and more. CGRP blockade removes one layer of input. But if the remaining layers are collectively sufficient to exceed threshold, the attack still happens.
This explains the "takes the edge off but doesn't stop it" experience. The drug is doing something: it's reducing CGRP-mediated input, but the other layers are still pushing the system over.
Pattern clue: CGRP drugs reduce severity but not frequency; attacks still happen, just feel slightly less severe.
What the 50% Non-Response Rate Actually Means
The 50% non-response rate in CGRP clinical trials is often framed as a limitation. It isn't. It's one of the most useful facts in migraine medicine.
Think about what that number means: in patients selected specifically because they had frequent, disabling migraine, giving them the most sustained CGRP suppression ever developed (monthly injections that maintain near-complete CGRP blockade 24/7), half of them saw no meaningful improvement. That's not a drug efficacy problem. It's evidence that migraine has at least two distinct populations: one where CGRP is the dominant driver, and one where it isn't.
If you're in the second group, the CGRP trials have essentially run a controlled experiment on your behalf. You've established that sustained, complete CGRP blockade doesn't resolve your migraines. That narrows the remaining search significantly, pointing toward the layers that weren't tested in those trials.
Track this pattern free
The fastest way to identify which layer is driving your attacks is to track the surrounding context day by day: cycle timing, food, sleep, posture, stress. The free Voice Tracker lets you speak or type your daily notes in Telegram and builds your pattern report automatically. No sign-up, no password.
Open Voice Tracker on Telegram →What CGRP Medications Can and Can't Do
Can do: Block CGRP-mediated vasodilation and neuroinflammation at the trigeminal level. Reduce attack frequency and severity when CGRP is the dominant driver. Provide the cleanest acute option for people who can't tolerate triptan vasoconstriction.
Can't do: Stabilize estrogen fluctuations. Reduce histamine load or mast cell reactivity. Improve cerebral perfusion in vascular underfill patterns. Address autonomic dysregulation. Reach the central sensitization that has developed in chronic migraine. Lower the overall threshold when multiple non-CGRP factors are stacking.
Useful even when partial: If a CGRP drug reduces attack severity without eliminating attacks, it may still be worth continuing while other layers are investigated. Reducing one major input can bring the threshold high enough that smaller reductions elsewhere tip the balance.
The gepant vs antibody distinction matters: Gepants (Nurtec, Ubrelvy) are small molecules with better central nervous system penetration; antibodies (Aimovig, Ajovy, Emgality) provide more sustained peripheral blockade. Some patients respond to one approach but not the other. See the Nurtec guide and Aimovig guide for mechanism differences.
How to Actually Investigate Non-CGRP Drivers
The layer-by-layer investigation approach works by identifying which inputs are most active in your system. For CGRP non-responders, the most productive layers to examine are usually:
Hormonal layer
Map attacks against your menstrual cycle for at least 3 months. If attacks cluster in the 2-3 days before menstruation or at mid-cycle, hormonal estrogen fluctuations are likely a major driver.
Histamine and inflammatory layer
Track food, flushing, and nasal symptoms alongside attacks. A 24-hour urine histamine test (Quest reference range: 0.006-0.131 mg/24h) can help quantify baseline histamine excretion. Low-histamine diet trial periods (typically 4-6 weeks) can clarify whether reducing dietary histamine load reduces attack frequency.
Vascular and autonomic layer
Orthostatic blood pressure testing (lying, sitting, standing measurements separated by 2 minutes each) can reveal POTS or low blood pressure patterns. Sodium and fluid intake history often correlates with attack timing in vascular-underfill patterns.
Threshold factors
Sleep quality, stress load, and hydration status are often the threshold-setting factors that determine whether any single day crosses into migraine territory. These are worth tracking alongside the specific layer investigations above.
Questions worth bringing to your clinician if CGRP medications haven't helped:
- "Given that both gepants and antibodies haven't helped, which non-CGRP pathways seem most likely based on my attack patterns?"
- "Is it worth testing for histamine intolerance or DAO deficiency before trying another medication class?"
- "Do my migraines follow a hormonal pattern that would suggest estrogen stabilization is worth investigating?"
- "Should we check orthostatic blood pressure to see whether vascular underfill is contributing?"
- "If CGRP isn't the driver, which layers in the threshold model seem most active in my pattern?"
If you've been on a specific CGRP drug without success, the individual mechanism guides cover the failure patterns in more detail: see why Nurtec fails (gepant-specific patterns including timing and absorption), and why Aimovig fails (antibody-specific patterns including centralization and side effect offset). The Emgality guide covers the molecule-blocker distinction from Aimovig.
For the broader framework, the threshold system guide explains how multiple inputs stack: why any single drug that targets one pathway can only do so much when the total load comes from several directions at once.
This guide is for education and pattern-recognition only. It is not medical advice and is not a plan to start, stop, or change any medication, supplement, or test. Always discuss treatment decisions with a licensed clinician who knows your history.
Clinical and Review Articles
- Goadsby PJ et al. A controlled trial of erenumab for episodic migraine. New England Journal of Medicine. 2017;377(22):2123-2132.
- Silberstein SD et al. Fremanezumab for the preventive treatment of chronic migraine. New England Journal of Medicine. 2017;377(22):2113-2122.
- Stauffer VL et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurology. 2018;75(9):1080-1088.
- Croop R et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine. The Lancet. 2019;394(10200):737-745.
- Edvinsson L et al. CGRP as the target of new migraine therapies: successful translation from bench to clinic. Nature Reviews Neurology. 2018;14(6):338-350.
- Levy D. Migraine pain, meningeal inflammation, and mast cells. Current Pain and Headache Reports. 2009;13(3):237-240.
Free checklist
Get the layer investigation checklist
One email. Four migraine layers most workups miss (hormonal, histamine, vascular, supplement form), with a pattern clue and first test for each.
Already have test results?
If you've accumulated years of normal tests but still have migraines, those records may contain patterns that haven't been examined together.
Related reading
This is educational content, not medical advice. Always consult a qualified clinician.